Latest filing published 13 Aug 2026 for Amneal Pharmaceuticals, Inc., €101k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jason B. Daly discloses dealings in Amneal Pharmaceuticals, Inc. to SEC (Form 4). Between 3 March 2023 and 12 August 2026, the trades on record add up to 11 filings.
The open-market record consists of 6 sales worth €4.3M, with no purchase. The rest of the record consists of 1 share grant and 4 option exercises. 2026 to date brings no purchases and 2 sales.
Most recently, on 13 August 2026, the filings show an open-market sale worth €101k in Amneal Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations